Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193823 | 0.77 | NPC1 (0.45) | ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL30537878 | 0.77 | LMNA (0.55) | ALDH1A1LMNACYP3A4MAPTPDE10A | |
| SCHEMBL18899026 | 0.73 | ACACB (0.37) | ALDH1A1LMNACYP3A4MAPTAPEX1 | |
| SCHEMBL17031856 | 0.73 | CASR (0.31) | ALDH1A1 | |
| SCHEMBL17040409 | 0.73 | NPC1 (0.43) | ALDH1A1MAPK1 | |
| SCHEMBL28577953 | 0.72 | KDM4E (0.41) | ALDH1A1LMNAMAPT | |
| SCHEMBL24402005 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL3096248 | 0.71 | LMNA (0.61) | ALDH1A1LMNAMAPTMAPK1PDE10A | |
| SCHEMBL6175735 | 0.71 | MEN1 (0.56) | ALDH1A1LMNAMAPTMAPK1PDE10A | |
| SCHEMBL28577760 | 0.70 | ADORA2A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | ALDH1A1 2219/4885LMNA 4007/4885CYP3A4 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.